1. Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.
- Author
-
Di Paola A, Palumbo G, Tortora C, Argenziano M, Catanoso M, Di Leva C, Ceglie G, Perrotta S, Locatelli F, and Rossi F
- Subjects
- Anti-Inflammatory Agents therapeutic use, Benzoates pharmacology, Benzoates therapeutic use, Child, Humans, Hydrazines pharmacology, Hydrazines therapeutic use, Iron therapeutic use, Pyrazoles, Mesenchymal Stem Cells, Purpura, Thrombocytopenic, Idiopathic drug therapy, Thrombocytopenia drug therapy
- Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease caused by platelet destruction mediated by auto-antibody production. It is characterized by a compromised immune system and alteration of the inflammatory response. Mesenchymal stromal cells (MSCs) play an important role in modulating immune and inflammatory processes, exerting immune-suppressing and anti-inflammatory properties. In ITP-MSCs the activity and survival are strongly impaired. Eltrombopag (ELT) is a thrombopoietin receptor agonist approved in chronic ITP for stimulating platelet production. It has immunomodulating properties by stimulating T and B regulatory cell activity and by promoting a macrophage switch from the pro-inflammatory to the anti-inflammatory phenotype. ELT also exhibits iron-chelating properties. Iron is a crucial element involved in several physiologic processes, but its intracellular accumulation determines cell damages. Therefore, for the first time we analysed the effect of ELT on ITP-MSCs demonstrating its ability to restore survival and activity of MSCs directly and to promote their survival and proliferation indirectly, by iron metabolism modulation., (© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF